STUDY OBJECTIVES: A single-item sleep quality scale (SQS) was developed as a simple and practical sleep quality assessment and psychometrically evaluated. METHODS:SQS measurement characteristics were evaluated using the Pittsburgh Sleep Quality Index (PSQI) and morning questionnaire-insomnia (MQI) according to prespecified analysis plans in separate clinical studies of patients with insomnia and depression. Patients with insomnia (n = 70) received 4 weeks' usual care with an FDA-approved hypnotic agent; patients with depression (n = 651) received8 weeks' active or experimental therapy. RESULTS: Concurrent criterion validity (correlation with measures of a similar construct) was demonstrated by strong (inverse) correlations between the SQS and MQI (week 1 Pearson correlation -.76) and PSQI (week 8 Goodman-Kruskal correlation -.92) sleep quality items in populations with insomnia and depression, respectively. In patients with depression, stronger correlations between the SQS and PSQI core sleep quality components versus other items supported convergent/divergent construct validity (similarity/dissimilarity to related/unrelated measures). Known-groups validity was evidenced by decreasing mean SQS scores across those who sleep normally, those borderline to having sleep problems, and those with problems sleeping. Test-retest reliability (intraclass correlation coefficient) was .62 during a 4-week period of sleep stability in patients with insomnia and .74 in stable patients with depression (1 week). Effect sizes (standardized response means) for change from baseline were 1.32 (week 1) and .67 (week 8) in populations with insomnia and depression, respectively. Mean SQS changes from baseline to week 8 convergently decreased across groups of patients with depression categorized by level of PSQI sleep quality improvement. CONCLUSIONS: The SQS possesses favorable measurement characteristics relative to lengthier or more frequently administered sleep questionnaires in patients with insomnia and depression. CLINICAL TRIAL REGISTRATION: Registry: ClincalTrials.gov, Title: Treatment of Patients With Major Depressive Disorder With MK0869, Identifier: NCT00034983, URL: https://clinicaltrials.gov/ct2/show/NCT00034983.
RCT Entities:
STUDY OBJECTIVES: A single-item sleep quality scale (SQS) was developed as a simple and practical sleep quality assessment and psychometrically evaluated. METHODS: SQS measurement characteristics were evaluated using the Pittsburgh Sleep Quality Index (PSQI) and morning questionnaire-insomnia (MQI) according to prespecified analysis plans in separate clinical studies of patients with insomnia and depression. Patients with insomnia (n = 70) received 4 weeks' usual care with an FDA-approved hypnotic agent; patients with depression (n = 651) received 8 weeks' active or experimental therapy. RESULTS: Concurrent criterion validity (correlation with measures of a similar construct) was demonstrated by strong (inverse) correlations between the SQS and MQI (week 1 Pearson correlation -.76) and PSQI (week 8 Goodman-Kruskal correlation -.92) sleep quality items in populations with insomnia and depression, respectively. In patients with depression, stronger correlations between the SQS and PSQI core sleep quality components versus other items supported convergent/divergent construct validity (similarity/dissimilarity to related/unrelated measures). Known-groups validity was evidenced by decreasing mean SQS scores across those who sleep normally, those borderline to having sleep problems, and those with problems sleeping. Test-retest reliability (intraclass correlation coefficient) was .62 during a 4-week period of sleep stability in patients with insomnia and .74 in stable patients with depression (1 week). Effect sizes (standardized response means) for change from baseline were 1.32 (week 1) and .67 (week 8) in populations with insomnia and depression, respectively. Mean SQS changes from baseline to week 8 convergently decreased across groups of patients with depression categorized by level of PSQI sleep quality improvement. CONCLUSIONS: The SQS possesses favorable measurement characteristics relative to lengthier or more frequently administered sleep questionnaires in patients with insomnia and depression. CLINICAL TRIAL REGISTRATION: Registry: ClincalTrials.gov, Title: Treatment of Patients With Major Depressive Disorder With MK0869, Identifier: NCT00034983, URL: https://clinicaltrials.gov/ct2/show/NCT00034983.
Authors: H A Lomeli; I Pérez-Olmos; C Talero-Gutiérrez; C B Moreno; R González-Reyes; L Palacios; F de la Peña; J Muñoz-Delgado Journal: Actas Esp Psiquiatr Date: 2008 Jan-Feb Impact factor: 1.196
Authors: Thomas Roth; Catherine Coulouvrat; Goeran Hajak; Matthew D Lakoma; Nancy A Sampson; Victoria Shahly; Alicia C Shillington; Judith J Stephenson; James K Walsh; Ronald C Kessler Journal: Biol Psychiatry Date: 2010-12-31 Impact factor: 13.382
Authors: Michael Littner; Max Hirshkowitz; Milton Kramer; Sheldon Kapen; W McDowell Anderson; Dennis Bailey; Richard B Berry; David Davila; Stephen Johnson; Clete Kushida; Daniel I Loube; Merrill Wise; B Tucker Woodson Journal: Sleep Date: 2003-09 Impact factor: 5.849
Authors: Michael Littner; Clete A Kushida; W McDowell Anderson; Dennis Bailey; Richard B Berry; David G Davila; Max Hirshkowitz; Sheldon Kapen; Milton Kramer; Daniel Loube; Merrill Wise; Stephen F Johnson Journal: Sleep Date: 2003-05-01 Impact factor: 5.849
Authors: Pei-Lin Yang; Robert L Burr; Diana T Buchanan; Kenneth C Pike; Kendra J Kamp; Margaret M Heitkemper Journal: J Clin Sleep Med Date: 2020-10-15 Impact factor: 4.062
Authors: Caitlan A Tighe; Daniel J Buysse; Debra K Weiner; Gregory P Beehler; Daniel E Forman Journal: J Cardiopulm Rehabil Prev Date: 2022-05-02 Impact factor: 3.646
Authors: Pradeep Suri; Adrienne D Tanus; Nikki Torres; Andrew Timmons; Bianca Irimia; Janna L Friedly; Anna Korpak; Clinton Daniels; Daniel Morelli; Paul W Hodges; Nathalia Costa; Melissa A Day; Patrick J Heagerty; Mark P Jensen Journal: BMC Musculoskelet Disord Date: 2022-04-21 Impact factor: 2.562
Authors: Elliottnell Perez; Paul B Perrin; Sarah K Lageman; Teresita Villaseñor; Joseph M Dzierzewski Journal: Disabil Rehabil Date: 2020-09-11 Impact factor: 2.439